CQ Medical Expands Its Radiation Therapy Line with Bionix Acquisition

CQ Medical, recognized as a leader in patient radiotherapy positioning and healthcare innovation, has announced the acquisition of the Radiation Therapy business unit from Bionix. This strategic move signifies CQ Medical’s commitment to enhancing its product portfolio dedicated to improving patient outcomes in radiotherapy across the globe.

Founded in 2022 through the merger of CIVCO Radiotherapy and Qfix, CQ Medical has quickly established itself in the market, combining decades of expertise and innovation in radiation therapy positioning and immobilization solutions. The company offers a diverse array of clinical applications, including precision stereotactic treatment and proton therapy devices, implantable fiducial markers for image-guided radiotherapy, customizable thermoplastic patient immobilization, and specialized patient transfer systems for both radiotherapy and interventional procedures such as cardiology and radiology.

The Bionix acquisition, which will allow CQ Medical to integrate additional high-quality product lines into its offerings, reflects a mutual dedication to quality and innovation shared between the two organizations. Michael Galbus, CEO of CQ Medical, expressed optimism about the partnership, stating, "The Bionix radiation therapy acquisition brings several complementary product lines to CQ Medical, as well as adding a strong commercial team from the Bionix organization. We look forward to the continued collaboration with our combined clinical partners to support the next generation of research and new product development."

Bionix has been a trusted name in the development of cutting-edge medical devices for over four decades. Renowned for its rigorous commitment to innovation and quality, Bionix will continue to operate its Ambulatory Care business unit independently, focusing on solutions within Ear, Nose, and Throat care. Chris Becker, President and CEO of Bionix, emphasized that partnering with CQ Medical will enable Bionix to concentrate fully on its core business areas, such as Primary Care, Urgent Care, Audiology, and ENT.

Moving forward, CQ Medical intends to transition Bionix’s radiation therapy product lines and operations into its existing facilities, ensuring that customers experience seamless continuity in service and support. Both companies are dedicated to maintaining the rigorous quality standards that have built their reputations over the years.

This acquisition is expected to significantly expand CQ Medical's footprint in the radiotherapy market, fostering improved clinical outcomes for patients worldwide. By leveraging Bionix's reputable portfolio of products and CQ Medical’s established expertise in radiotherapy, clinicians will have enhanced tools to ensure effective treatment delivery.

For more information and the latest updates about this acquisition and other advancements in radiotherapy, please visit CQ Medical's official website or connect with them on LinkedIn and Facebook.

In summary, CQ Medical's acquisition of Bionix’s Radiation Therapy unit marks a significant step forward in the field of patient radiotherapy positioning, underscoring both companies' shared commitment to delivering innovative and effective healthcare solutions.